Analytical Data
-
Gene name
PSG2
- Application
-
Alternative Names
CEA; PSG1; PSBG2; PSGGB; Carcinoembryonic Antigen SG8; Pregnancy-specific glycoprotein 2; Pregnancy-specific beta-1 glycoprotein E
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11465
-
Expression Region
Gln35~Thr335
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSG2 (Pregnancy-Specific Glycoprotein 2) is a member of the PSG protein family, primarily expressed in the placenta during pregnancy. Research on PSG2 has gained momentum due to its potential roles in immune modulation and trophoblast function, which are crucial for successful implantation and maintenance of pregnancy. The protein contains multiple glycosylation sites that influence its biological activity and interactions with maternal immune cells, suggesting a role in protecting the fetus from maternal immune rejection. Additionally, PSG2 has been implicated in various pathological conditions, including cancer, where it may influence tumor growth and immune evasion. Its diverse functionalities have prompted investigations into its therapeutic potential and its applicability as a biomarker for pregnancy-related complications and certain cancers. Recent advances in molecular biology techniques have facilitated better understanding of PSG2’s structure and function, paving the way for further studies aimed at elucidating its mechanisms and determining its clinical relevance. Therefore, research on PSG2 not only contributes to the understanding of reproductive biology but also opens avenues for novel therapeutic strategies in oncology and obstetrics.
